Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.

Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.

J Med Econ. 2013;16(4):468-78. doi: 10.3111/13696998.2013.768999. Epub 2013 Feb 6.

PMID:
23384160
2.

Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.

Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.

Diabet Med. 2012 Mar;29(3):303-12. doi: 10.1111/j.1464-5491.2011.03461.x.

PMID:
21951030
3.

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.

J Med Econ. 2012;15(5):977-86. doi: 10.3111/13696998.2012.692340. Epub 2012 May 23.

PMID:
22563742
4.

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84. doi: 10.1185/03007990902869169 .

PMID:
19366302
5.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

6.

Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.

Jendle J, Ridderstråle M, Torfvitt O, Ericsson A, Larsen S.

J Med Econ. 2012;15(2):261-3. doi: 10.3111/13696998.2011.644408. Epub 2011 Dec 6.

PMID:
22142237
8.

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.

Ericsson Å, Pollock RF, Hunt B, Valentine WJ.

J Med Econ. 2013 Dec;16(12):1442-52. doi: 10.3111/13696998.2013.852099. Epub 2013 Oct 25.

PMID:
24147661
9.

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. Review.

PMID:
17443605
10.

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.

Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.

Adv Ther. 2007 Mar-Apr;24(2):273-90.

PMID:
17565917
11.

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.

Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K.

Adv Ther. 2008 Jun;25(6):567-84. doi: 10.1007/s12325-008-0069-z.

PMID:
18568451
12.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Review.

15.

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.

Frier BM, Russell-Jones D, Heise T.

Diabetes Obes Metab. 2013 Nov;15(11):978-86. doi: 10.1111/dom.12106. Epub 2013 May 1. Review.

PMID:
23551900
16.

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.

Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P.

Diabetes Technol Ther. 2012 Jan;14(1):65-73. doi: 10.1089/dia.2011.0092. Epub 2011 Nov 8.

PMID:
22066527
17.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
18.

Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.

Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.

J Med Econ. 2012;15 Suppl 2:14-27. doi: 10.3111/13696998.2012.713879. Epub 2012 Aug 3.

PMID:
22812690
19.

Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.

Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1326-35. doi: 10.1002/pds.3534. Epub 2013 Oct 21.

20.

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.

Ericsson Å, Lundqvist A.

Appl Health Econ Health Policy. 2017 Apr;15(2):237-248. doi: 10.1007/s40258-016-0301-y.

Supplemental Content

Support Center